Saturday 17 October 2026
Export XAGE’s income statement to Excel — free account
Longevity Health Holdings, Inc.
XAGE Consumer Defensive Household & Personal Products
Longevity Health Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, up 3,702.8% from fiscal 2024. In the quarter to June 2026, revenue fell 21.4%, EPS grew 51.3% and free cash flow grew 73.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.11
0.00
0.00%
Follow XAGE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.38 | 0.31 | 0.22 | 0.84 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.87) | (1.14) | (1.40) | (0.85) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.25 | 0.97 | 0.64 | 1.11 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.86) | (0.57) | (0.37) | (0.42) | |
EV/FCF |
(0.85) | (0.56) | (0.36) | (0.42) | |
Quick Ratio |
0.01 | 0.04 | 0.09 | 0.21 | |
Current Ratio |
0.07 | 0.15 | 0.25 | 0.42 | |
Net Debt/EBITDA |
0.05 | 0.24 | 0.32 | 0.77 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.71 | 0.72 | 1.00 | 0.51 | |
Operating CF/Net income |
0.12 | 0.34 | 0.15 | 1.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.38) | |
Interest Coverage |
(329.18) | (379.57) | (405.57) | (288.43) | |
Research and Development Expense of Revenue |
18.54% | 14.17% | 28.63% | 53.53% | |
Selling, General and Administrative Expense of Revenue |
220.45% | 381.57% | 504.74% | 347.78% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.00 | |
Share Based Compensation of Revenue |
19.90% | 37.24% | 40.95% | 44.59% | |
Graham Net Nets |
(14.05) | (13.20) | (14.65) | (3.62) | |
Graham Number |
16.61 | 18.72 | 21.62 | 16.55 | |
Earnings Yield |
(1,342.31%) | (1,479.31%) | (1,686.67%) | (743.13%) | |
Free Cash Flow Yield |
(382.80%) | (558.25%) | (779.59%) | (313.80%) | |
Revenue per Share |
0.16 | 0.21 | 0.33 | 0.25 | |
Operating CF per Share |
(0.09) | (0.26) | (0.21) | (0.83) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.09) | (0.26) | (0.21) | (0.84) | |
Cash per Share |
0.01 | 0.17 | 0.49 | 0.64 | |
Shareholders Equity per Share |
(3.51) | (3.63) | (4.10) | (2.31) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(3.51) | (3.63) | (4.10) | (2.31) | |
Free Cash Flow |
(0.22) | (0.49) | (0.31) | (1.45) | |
Working Capital |
(8.88) | (7.09) | (5.97) | (4.00) | |
Capital Expenditures |
— | — | 0.00 | (0.01) | |
Net Current Asset Value |
(9.04) | (7.27) | (6.28) | (4.43) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.19 | 0.22 | 0.17 | 0.28 | |
Average Payables |
4.82 | 4.82 | 4.28 | 4.19 | |
Average Inventory |
0.89 | 1.06 | 0.54 | 0.56 | |
Average Assets |
2.39 | 2.49 | 1.92 | 2.87 | |
Average Common Equity |
(6.22) | (5.35) | (5.29) | (4.02) |
Columns are period end dates